CXI Healthcare CEO LIN JINSHENG Plans Open Market Purchase of 700,000 Shares, Signaling Control Strengthening and Price Support
LIN JINSHENG, CEO and de facto controlling shareholder of CXI Healthcare Technology Group, disclosed a plan to purchase 700,000 common shares via open market trading over 30 days from October 8 to November 6, 2026.
The estimated purchase price is 1,081 KRW per share based on the closing price before filing, totaling approximately 756.7 million KRW. Post-purchase, his stake will increase from 27.93% to 32.13%.
This follows recent acquisitions of 8.48 million shares through third-party allotments in the past six months, indicating a strategy to strengthen control and enhance long-term value. Since open market purchases do not involve new share issuance, there is no dilution for existing shareholders, but reduced free float may provide short-term price support.
[AI Summary]The CEO's voluntary open market purchase signals management confidence and could provide downside price protection. However, given the significant dilution from prior private placements, short-term upside may be limited. The transaction size, about 9% of market cap, supports improved supply-demand dynamics.
KOSDAQ Filing Information
Report On Transaction Plan Of Specific Securities By Executives And Major Shareholders